The company said, “We are pleased to see the pieces of our multi-year strategy coming together, which has made us confident in communicating our 2024-2027 guidance. By 2027, we anticipate substantial value creation by achieving the following: Revenue to increase by 163%, from $59.35M in 2024 to $155.8M in 2027. Gross profit to grow by 653%, from $6.25M in 2024 to $47.06M in 2027. Gross profit margin to expand by 1,970 basis points, from 10.50% in 2024 to 30.20% in 2027. Net income to increase by 402%, reaching $20.44M in 2027, compared to a loss of $6.76M in 2024. Adjusted EBITDA to grow to $29.4M in 2027, from a loss of $1.21M in 2024.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on COSM:
- Cosmos Health files to sell 9.75M shares of common stock for holders
- Cosmos Health reports 160% increase in 2024 YTD sales on Amazon UK
- Cosmos Health enters exclusivity agreement with Virax Biolabs
- Cosmos Health secures exclusivity agreement with Virax Biolabs
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
